Basic Research

Study on the mechanism of polyethylene glycol losenatide improving non⁃alcoholic fatty liver disease by regulating lipophagy

  • Xunxun CHEN ,
  • Jielei ZHANG
Expand
  • Department of Endocrinology and Metabolic Diseases,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan,China

Received date: 2025-02-25

  Online published: 2025-06-19

Abstract

Objective To investigate the mechanism of polyethylene glycol losenatide in improving non-alcoholic fatty liver disease by regulating lipophagy. Methods (1) 32 C57BL/6 male mice were fed normally for 1 week and randomly divided into 4 groups with 8 mice in each group. Normal control group (fed normal diet), Normal + GLP-1RA (intraperitoneal injection of polyethylene glycol losenatide 0.3 mg/kg q3d), High fat group (fed with high fat diet), High-fat + GLP-1RA (on the basis of high-fat diet, intraperitoneally injected polyethylene glycol losenatide 0.3 mg/kg q3d), The molding lasts 16 weeks. Body weight, blood glucose and glucose tolerance test (GTT) were measured at the end of 16 weeks. Serum total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) and other indexes were detected by Enzyme-linked immunosorbent assay (ELISA), liver pathological changes were observed by Hematoxylin-eosin (HE) and oil red O sections, and the expression of microtubule-associated protein light chain 3 (LC3), autophagy adaptor protein (P62), and transcription factor EB (TFEB). in liver were detected by Western blot (Wb). (2) The cell was divided into normal group (treated with bovine serum albumin, BSA); Normal + polyethylene glycol losenatide group (BSA+100 nmol/L GLP-1RA), High fat group (0.5 mmol/L PA); High fat + polyethylene glycol losenatide group (0.5 mmol/L PA+100 nmol/L GLP-1RA). After 24 h, the steatosis was observed by oil red O staining, the levels of TG in the supernatant were detected, Wb analysis was performed to detect protein expression levels of LC3, TFEB, and P62. Reverse transcription quantitative PCR (RT-qPCR) was used to measure mRNA levels of lipid synthesis-related factors. Results (1) Compared with normal control group, the body weight and blood glucose of mice in the high fat group increased significantly (P < 0.01), reduced glucose tolerance (P < 0.01), the levels of TC,TG and LDL in serum in liver of high fat group were significantly increased (P < 0.01), while HDL was significantly decreased (P < 0.01). Compared with high fat group,blood sugar in mice, the levels of TC, TG and LDL in serum and P62 in liver of high fat + GLP-1 group were significantly decreased (P < 0.01); Glucose tolerance, HDL and and the protein expressions of LC3, TFEB were significantly increased (P < 0.01). Compared with normal control group, the above indexes in normal + GLP-1 group were not significantly changed (P > 0.05). (2) In vitro, The NAFLD HepG2 cell model was successfully constructed with 0.5 mmol/L PA. After 24 h of PA treatment, intracellular lipid drops were significantly increased (P < 0.01), intracellular TG and the mRNA levels of lipid synthesis-related factors in the cells were increased (P < 0.01). High fat + GLP-1 group improved the fatty degeneration induced by high fat, and the changes of the above indexes showed an opposite trend but the expression of LC3, TFEB were significantly increased (P < 0.01), lipid regulatory factor P62 protein in liver were decreased (P < 0.01). Conclusion Polyethylene glycol losenatide can improve non-alcoholic fatty liver disease by regulating lipophagy.

Cite this article

Xunxun CHEN , Jielei ZHANG . Study on the mechanism of polyethylene glycol losenatide improving non⁃alcoholic fatty liver disease by regulating lipophagy[J]. The Journal of Practical Medicine, 2025 , 41(11) : 1611 -1617 . DOI: 10.3969/j.issn.1006-5725.2025.11.002

References

1 MIRANDA MANRIQUE G. Parámetros metabólicos en pacientes con esteatosis hepática no alcohólica y diabetes tipo 2 controlados versus no controlados [Metabolic parameters in patients with steatosis non alcoholic liver and controlled diabetes type 2 versus uncontrolled diabetes type 2] [J]. Rev Gastroenterol Peru, 2016, 36(4): 336-339.
2 SHIN D W. Lipophagy: Molecular Mechanisms and Implications in Metabolic Disorders [J]. Mol Cells, 2020, 43(8): 686-693.
3 ZHANG S, PENG X, YANG S, et al. The regulation, function, and role of lipophagy, a form of selective autophagy, in metabolic disorders [J]. Cell Death Dis, 2022, 13(2): 132. doi:10.1038/s41419-022-04593-3
4 DRUCKER D J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 [J]. Cell Metab, 2018, 27(4): 740-756. doi:10.1016/j.cmet.2018.03.001
5 VISWANATHAN P, CHAUDHURI A, BHATIA R, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin [J]. Endocr Pract, 2007, 13(5): 444-450. doi:10.4158/ep.13.5.444
6 KLONOFF D C, BUSE J B, NIELSEN L L, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years [J]. Curr Med Res Opin, 2008, 24(1): 275-286. doi:10.1185/030079908x253870
7 DONG Y, LV Q, LI S, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis [J]. Clin Res Hepatol Gastroenterol, 2017, 41(3): 284-295. doi:10.1016/j.clinre.2016.11.009
8 BEN-SHLOMO S, ZVIBEL I, SHNELL M, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase [J]. J Hepatol, 2011, 54(6): 1214-1223. doi:10.1016/j.jhep.2010.09.032
9 肖艳新, 赵立威, 李立琴, 等. 度拉糖肽对肥胖2型糖尿病合并非酒精性脂肪性肝病患者肝脏脂肪含量的影响 [J]. 浙江医学, 2023, 45(20): 2153-2157. doi:10.12056/j.issn.1006-2785.2023.45.20.2022-981
10 REZAEI S, TABRIZI R, NOWROUZI-SOHRABI P, et al. GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis [J]. Can J Gastroenterol Hepatol, 2021, 2021: 8936865. doi:10.1155/2021/8936865
11 李晓娟. 聚乙二醇洛塞那肽对T2DM糖脂代谢和胰岛功能的影响 [J]. 糖尿病新世界, 2023, 26(22): 96-99.
12 屈昌会, 史保强, 王娟, 等. 聚乙二醇洛塞那肽与二甲双胍联合治疗对初诊肥胖2型糖尿病患者糖脂代谢的影响 [J]. 中国实用医药, 2024, 19(15): 119-122.
13 王燕, 张秀娟. 聚乙二醇洛塞那肽对肥胖2型糖尿病患者体质量、腰围和内脏脂肪面积的影响 [J]. 山东医药, 2022, 62(25): 35-38. doi:10.3969/j.issn.1002-266X.2022.25.008
14 孙瑶环. GLP-1受体激动剂治疗T2DM合并MAFLD的临床证据总结及疗效研究 [D]. 南京:南京中医药大学, 2024.
15 LI Y, CHEN Y. AMPK and Autophagy [J]. Adv Exp Med Biol, 2019, 1206:85-108. doi:10.1007/978-981-15-0602-4_4
16 KMA L, BARUAH T J. The interplay of ROS and the PI3K/Akt pathway in autophagy regulation [J]. Biotechnol Appl Biochem, 2022, 69(1): 248-264. doi:10.1002/bab.2104
17 LIU K, QIU D, LIANG X, et al. Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy [J]. Autophagy, 2022, 18(4): 860-876. doi:10.1080/15548627.2021.1961072
18 MIN Y, KIM M-J, LEE S, et al. Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NFKB activation and autophagy activation [J]. Autophagy, 2018, 14(8): 1347-1358. doi:10.1080/15548627.2018.1474995
19 LUO R, SU L-Y, LI G, et al. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model [J]. Autophagy, 2020, 16(1): 52-69. doi:10.1080/15548627.2019.1596488
20 SCORLETTI E, CARR R M. A new perspective on NAFLD: Focusing on lipid droplets [J]. J Hepatol, 2022, 76(4): 934-945. doi:10.1016/j.jhep.2021.11.009
Outlines

/